Lose weight by 13.1% in 12 weeks! Novo Nordisk's new generation oral weight loss therapy data released
I'm PortAI, I can summarize articles.
Novo Nordisk announced the Phase I study data of the oral weight-loss drug Amycretin (NN9487) at the EASD annual meeting, showing an average weight reduction of 13.1% in the 100mg dose group. The drug is a GLP-1R/AMYR agonist, with an oral dosage form taken once daily. The study results indicate significant weight loss effects in the 50mg and 100mg dose groups, which were 10.4% and 13.1% respectively, while the placebo group was only 1.1%. Novo Nordisk plans to decide whether to proceed directly to Phase III study after obtaining the Phase I study data of NN9490 next year
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments